Eli Lilly stock loses 0.46 percent pre-market to EUR 1042.80
Published on 10/14/2026 at 07:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming results and valuation
- Eli Lilly is scheduled to report third-quarter results on October 29, 2026.
- Eli Lilly stock trades pre-market at EUR 1042.80 at 7:31 a.m. CEST at Lang & Schwarz on October 14, 2026, 0.46 percent below the Xetra close of October 13, 2026.
- The company's price-earnings ratio was 39.14 as of October 14, 2026.
Eli Lilly stock trades pre-market at EUR 1042.80 at 7:31 a.m. CEST at Lang & Schwarz on October 14, 2026, down 0.46 percent versus the Xetra close of October 13, 2026 at EUR 1047.60. The bid was EUR 1041.60 and the ask was EUR 1044.00.
Trading levels before the bell
The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
What matters today. Eli Lilly is scheduled to report third-quarter results on October 29, 2026, according to a report by The Motley Fool. A move to EUR 1050.00 would place the stock 0.69 percent above the Xetra close of October 13, 2026. Finance data showed a price-earnings ratio of 39.14 as of October 14, 2026.
Upcoming earnings date
The October 29 reporting date is the next company-specific event identified in the available coverage. The October 13 report said investors are expected to focus on sales of Mounjaro and Zepbound when Lilly reports its third-quarter results. The Motley Fool also reported that Lilly plans to submit retatrutide for FDA approval in the first quarter of 2027.
Market context: Market report S&P 500.
